A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

Suzhou Sanegene Bio

Status and phase: Not yet enrolling; Phase 2

Conditions: C3 Glomerulopathy; IgA Nephropathy (IgAN); IC-MPGN

Treatments: Drug: SGB-9768

Study type: Interventional

Funder types: Industry

Identifiers

NCT06786338

SGB-9768-003

Details and patient eligibility

About

This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.

Full description

This is a phase 2, multicenter, open-label study to evaluate of the efficacy and safety of SGB-9768 in patients with primary IgA nephropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis. The primary objective is to evaluate efficacy of SGB-9768 in reducing urine protein excretion and maintain kidney function in these patients. Secondly, safety, pharmacokinetics and pharmacodynamics will be charaterized.

Enrollment: 38 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥18 years
• Weight ≥40 kg, with a body mass index (BMI) between 15 and 35 kg/m²
• Biopsy-confirmed diagnosis of primary IgA nephropathy, C3 glomerulopathy or IC-MPGN, accompanied by C3 deposition in the glomeruli.
• Urine protein-to-creatinine ratio (UPCR) ≥0.75 g/g
• Estimated glomerular filtration rate (eGFR) (calculated using the CKD-EPI formula) must be ≥30 mL/min/1.73 m².
• Must be on a stable maximum tolerated doses of ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) for at least 12 weeks
• Participants of childbearing potential must use highly effective contraception during the study and for at least 12 weeks following the end of the study or last dose of study drug

Exclusion criteria

• Kidney biopsy indicates more than 50% tubular atrophy or interstitial fibrosis.
• Kidney biopsy shows more than 50% formation of glomerular crescents, or clinical signs suggestive of rapidly progressive glomerulonephritis.
• IgA nephropathy, C3 glomerulopathy, or IC-MPGN secondary to other diseases
• Presence of other systemic diseases or kidney diseases that may cause proteinuria
• Received immunosuppressants or other immunomodulators within 90 days prior to the first administration of the investigational drug
• Received B-cell targeted biologics or other biologics within 180 days prior to the first administration of the investigational drug
• Used SGLT2 inhibitors or endothelin receptor antagonists, unless have been stably used for 12 weeks or more
• Significant comorbidities
• History of any malignant tumors of any organ system within the past 5 years
• History of severe trauma or major surgery within 12 weeks prior to screening, or plans to undergo surgery during the study.
• History of immunodeficiency diseases, congenital asplenia or splenectomy.
• History of recurrent invasive infections, active systemic bacterial, viral, or fungal infections
• Positive test results for HBV, HCV, HIV
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels > 2.5 times the upper limit of normal (ULN)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

38 participants in 3 patient groups

IgAN-1

Experimental group

Description:

2 doses of SGB-9768 by subcutaneous (sc) injection

Treatment:

Drug: SGB-9768

IgAN-2

Experimental group

Description:

2 doses of SGB-9768 by subcutaneous (sc) injection

Treatment:

Drug: SGB-9768

C3G/IC-MPGN

Experimental group

Description:

2 doses of SGB-9768 by subcutaneous (sc) injection

Treatment:

Drug: SGB-9768